Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Register Now For No-Deal Brexit Ferry Routes, Says BIA

Time Is Running Short As A Deal Looks Unlikely

Executive Summary

Life science firms wanting to avoid possible blockages at the Channel ports if the UK leaves the EU without a deal are being advised by the BioIndustry Association to register now. Meanwhile the government has published a report that brings together all its advice on preparing for a no-deal Brexit.

You may also be interested in...



UK Govt About To Reveal No-Deal Brexit Ferry Routes

The UK government is to write to companies explaining which ferry routes will be open to them when transporting medicines in a no-deal Brexit situation, and how to book space on the ferries. But it's all very last-minute as the Brexit date of 31 October draws near.

UK Audit Office Warns On No-Deal Brexit Medicines Supply

A lot of work has gone into planning for the impact of a no-deal Brexit on the UK medicines sector, but with only a month to go much remains to be done to ensure the country has the capacity to handle supply chain disruptions, says the National Audit Office.

2020 Sees Sharp Rise In EU New Drug Approvals

The number of new drugs containing new active substances approved in the EU rose significantly in 2020, underpinned by a strong showing for orphan-designated products and a string of novel medicines for cancer and infectious diseases. Notable among the new clutch of approvals was the first ever COVID-19 vaccine, Pfizer/BioNTech's Comirnaty.

Topics

UsernamePublicRestriction

Register

PS063835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel